Formycon

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars.

[Formycon @formycon]

Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026
https://t.co/CMJ1GaoRL3

[Formycon @formycon]

Formycon invites to conference call on the results of the first quarter of 2026. The conference call will take place on Thursday, May 28, 2026, at 3:00 PM (CEST) in English: https://t.co/L8JC2BVItr

[Formycon @formycon]

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧’𝐬 𝐚𝐟𝐥𝐢𝐛𝐞𝐫𝐜𝐞𝐩𝐭 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞: https://t.co/VTMIb7JR0p

[Formycon @formycon]

For information on the 2025 financial results and the outlook for 2026, please refer to our corporate news: https://t.co/qbSJSeQT7v
For full details on the financial results, please refer to the Annual Report on our website: https://t.co/lp7v1gHTgp

[Formycon @formycon]

𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐂𝐚𝐥𝐥
𝐨𝐧 𝐭𝐡𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐅𝐢𝐬𝐜𝐚𝐥 𝐘𝐞𝐚𝐫
To follow the conference live, please register via the following link: https://t.co/406YS29DRK
Access the replay at: https://t.co/oFL41dd7vw

[Formycon @formycon]

The European Biotechnology Science & Industry Guide is more than just a “Who's Who” of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.

[Formycon @formycon]

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐞𝐜𝐮𝐫𝐞𝐬 𝐥𝐢𝐜𝐞𝐧𝐬𝐞 𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐅𝐘𝐁𝟐𝟎𝟑 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 𝐚𝐧𝐝 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐭𝐞𝐫𝐫𝐢𝐭𝐨𝐫𝐢𝐞𝐬
Market launches by commercialization partners across Europe to start in May 2026
https://t.co/RB5NLK8Tmt

[Formycon @formycon]

🔬
Dahlia study demonstrates PK equivalence of FYB206 with the reference drug Keytruda®
https://t.co/nDFFuVyQ6F

[Formycon @formycon]

We are happy to announce another milestone in our global commercialization journey for FYB206:
https://t.co/dIIjybWliV

[Formycon @formycon]

The FDA has approved Nufymco®, another interchangeable #ranibizumab #biosimilar in the U.S., underscoring Formycon’s pioneering position in high-quality biosimilar #development: https://t.co/5KmDPzlqje

[Formycon @formycon]

Zydus Lifesciences Limited to commercialize Formycon’s Keytruda biosimilar FYB206 in the US and Canada: https://t.co/BxiK0DBO1s

[Formycon @formycon]

Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytruda® biosimilar candidate in the #MENA region: https://t.co/yeFWMXSLma

[Formycon @formycon]

Immunological Dupilumab Biosimilar Candidate FYB208 as another growth driver in Formycon's portfolio
https://t.co/Sq2uMQpUMo

[Formycon @formycon]

#WorldPsoriasisDay
Psoriatic Disease and Comorbidities -
Early Diagnosis and proper Treatment save Lives
https://t.co/LZJJdr8Gu3

[Formycon @formycon]

Formycon sets a new standard: FYB201/Ranivisio®is the first ranibizumab biosimilar on the European market in a pre-filled syringe presentation

For more information, please check our press release at:
https://t.co/EHdYasvJR4

[Formycon @formycon]

Additional commercialization partnerships for FYB203 to open up further important regions of the world:
https://t.co/v275LKXNq2

[Formycon @formycon]

Preserving vision –
Anti-VEGF therapies for severe retinopathies

👁️​ On World Sight Day, we we are turning our attention to retinopathies, in other words: diseases of the retina that can be responsible for severe visual impairment and even blindness: https://t.co/AWCkfc2sUK

[Formycon @formycon]

Formycon and Klinge expand their European commercialization strategy for the Eylea® biosimilar FYB203 with Horus Pharma as additional commercialization partner

https://t.co/7iezdpV7W7

[Formycon @formycon]

Dr. Andreas Seidl, Chief Scientific Officer (CSO) of Formycon AG, is Key Expert Speaker and Chairperson of today's first day of the 15th Biosimilars & Biologics Congress 2025 Europe in London.

[Formycon @formycon]

Formycon publishes financial results of H1 2025
https://t.co/OjhGG1390c